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the southern region of the USA had a higher costs compared to east, Midwest, and 
west regions (paid amount $3720 vs $3592 vs $3673 vs $2613). ConClusions: The 
cost of Teriflunomide treatment for RRMS patients is higher and costing the health 
plan around $3552 per month. The cost of the drug treatment was higher in southern 
of the USA and males were paying more in general.
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objeCtives: To assess the cost-effectiveness of natalizumab (NAT) as first-line 
treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (HARRMS) ver-
sus pooled interferon-beta (IFN) and glatiramer acetate (GA) from the Brazilian 
Public Healthcare (SUS) perspective. Natalizumab is currently only reimbursed for 
RRMS patients that failed therapy with IFN and GA. Currently, no guidance exist 
for patients with HARRMS in Brazil. Methods: A microsimulation model was 
developed with yearly cycles over a 20-year time horizon. Four different treatment 
sequences are included in the model: T1= NAT-IFN-GA, T2= NAT-GA-IFN, T3= IFN-
GA-NAT and T4= GA-IFN-NAT, allowing treatment failures [i.e., > = 1-point increase 
in the Expanded Disability Status Scale (EDSS)] to alternate therapies. Patients may 
experience EDSS progression, relapses, remain stable, discontinue treatment, or 
die. Natural history was parameterized from the 2005 UK MS Survey. Efficacy, utili-
ties and safety/discontinuation data were derived from respective pivotal trials. 
HARRMS was defined as > 2 disabling relapses in previous year and > 1 gadolinium-
enhancing lesions or a significant increase in T2 lesions. Direct costs were from gov-
ernment reimbursement lists (i.e., DATASUS, BPS, SIGTAP), discounted at 5% yearly, 
and reported in Brazilian currency (1BRL= 0.35USD). Consequences were assessed 
in quality adjusted life years (QALY). Monte-Carlo first-order was used. Results: 
Natalizumab as first-line for HARRMS (sequences T1 and T2) was considered cost-
effective in comparison to sequences T3 and T4 (standard practice). Total costs 
(K= thousands) and QALYs for each treatment arm were: T4= BRL187K/5.43QALY, 
T3= BRL203K/5.41QALY, T2= BRL227K/7.02QALY and T1= BRL228K/7.01QALY. The 
incremental cost-effectiveness ratio (ICER) for T1 and T2 relative to the least costly 
sequence (T4) were BRL25,258/QALY and BRL26,324/QALY respectively, and consid-
ered acceptable assuming a threshold of 3x the national gross domestic product 
(GDP) per capita (~BRL70,000/QALY). ConClusions: Since patients with HARRMS 
experience higher relapse rates and faster disability progression than the general 
RRMS population, natalizumab as first-line option is cost-effective and brings addi-
tional benefits to Brazilian patients.
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objeCtives: Evaluate the costs and socioeconomic aspects of Immunoglobulin 
replacement therapy in patients with Primary Immunodeficiency (PID) treated 
at a Public health clinic in Brazil. Methods: Transversal study with 42 patients 
who are being treated with intravenous immunoglobulin (IVIG) at the Division 
of Allergy Clinical Immunology and Rheumatology, Federal University Federal of 
São Paulo. Costs data were obtained from patient charts and Ministry of Health 
public reimbursement prices during the year of 2014. Socioeconomic data were 
obtained from a questionnaire answered by patients or their caregivers. A cost-
minimization modeling was performed comparing intravenous and subcutaneous 
routes. Results: Median patient age was 17 years old (6 months - 58 years) and 
71% were male. Mean IVIG dose was 639 mg/kg (400-1000 mg) under a 4 weeks 
regimen. Seventy-one percent of patients used public transportation, with mean 
daily expenditure (MDE) of R$ 19 and median duration of locomotion (MDL) of 4h 
(2:00-9:30); 25% used their own vehicle, with MDE of R$ 39 (0-100.00) and MDL of 
3:00h (0:45 to 4:45); 4% utilized an ambulance for transportation, with a MDL of 9:45h 
(5:00-14:30). Mean direct medical costs (drugs, infusion sets and health professional 
and administrative salaries) were R$ 2,298/patient/year for intravenous adminis-
tration. Thirteen school/ workdays were lost per year in this group, with a mean 
impact of RS 796/year/patient. Total cost (mean) of IVIG replacement was R$ 34,169/
patient/year while for subcutaneous route the cost calculated was R$ 32,245year (an 
R$ 1.833 difference). A 3 year cost minimization modeling comparing intravenous 
to subcutaneous route showed an average difference of R$ 1,128 per patient/year 
favoring the subcutaneous route. ConClusions: This is first study evaluating the 
cost of immunoglobulin replacement therapy in PID patients in Brazil. The cost-
minimization analysis showed that the choice of subcutaneous route could bring 
benefits for the Public Health System.
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objeCtives: To describe the profile of medicines procurement for Alzheimer’s 
disease (AD) in a Brazilian federal database. Methods: This study investigated 
procurement of medicines for AD in the Sistema Integrado de Administração de 
Serviços Gerais (SIASG). A profile of purchases, expenditures and prices from 2008 
to 2013 was drawn. The following medicines used for treatment of AD — donepezil, 
galantamine, rivastigmine and memantine — in several dosage forms were investi-
gated, including those not present in the Brazilian guidelines (PCDT). The extracted 
contributed up to 2.4% of the total cost for meningococcal disease in Chile, in 
contrast to 1.7% and 1.3% of the total cost estimated in Colombia and Panama, 
respectively. ConClusions: Findings of this study underscore the importance of 
meningococcal disease in the region in terms of cost. Future research should focus 
on more detailed investigation of costs of meningococcal cases and outbreaks from 
the societal perspective.
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objeCtives: The objective of this study is to assess the health care costs associated 
with Disease Modifying Therapies (DMTs) for patients diagnosed with Relapsing 
Remitting Multiple Sclerosis (RRMS). Methods: A large US administrative retro-
spective claims database was used to identify patients diagnosed with RRMS and 
were prescribed DMTs between January 2010 to December 2012 were included in 
the study. All patients were ≥ 18 years of age and continuously enrolled in the same 
health plan for at least a year. Descriptive statistics were performed on the data 
where appropriate. Results: There were a total of 741,065 patients that met the 
study inclusion criteria. Patients on average were charged $4161.40 ± 2817.59 for 
their DMTs treatment during the study period. However, the allowed amount by 
the health plan was $3681.33 ± 1847.82 and the actual paid amount was $3580.63 
± 1859.14. On average, patient’s deductible was $21.72 ± 228.50 and patient co-
payment was $82.94 ± 285.47. For patients whose prescription was on their health 
plans formulary paid on average higher costs compared to patients who were not 
(paid amount $3595 vs $3370; allowed amount $3686 vs 3493). Even though most 
of the patients were females, but they had overall lower costs compared to males 
(amount allowed $3677 vs $3689; paid amount $3576 vs $3590; deductible $21 vs $23; 
co-payment $82 vs $84). Patients who received treatment in the Midwest region of 
the USA had a higher costs compared to east, south, and west regions (paid amount 
$3672 vs $3596 vs $3468 vs $3461). ConClusions: The mean cost of treatment with 
any DMTs for the treatment of RRMS patients is $4161. The drug formulary status 
did not play a role in determining overall healthcare costs. Females and patients 
from Midwest region generally had higher costs.
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objeCtives: The objective of this study is to assess the health care resource utiliza-
tion and costs associated with Disease Modifying Therapies (DMTs) for pediatric 
patients diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS). Methods: 
A large US administrative retrospective claims database was used to identify 
patients diagnosed with RRMS and were prescribed DMTs between January 2010 to 
December 2012 were included in the study. All patients were ≤ 17 years of age and 
continuously enrolled in the same health plan at least for a year. Results: There 
were a total of 359 patients that met the study inclusion criteria and they were on 
the following DMTs: Gilenya (N= 7 (1.9%)), Extavia (N= 17 (4.7%)), Rebif (N= 32 (8.9%)), 
Copaxone (N= 117 (32.6%)), Avonex (N= 108 (30.1%)), and Betaseron (N= 78 (21.7%)). 
Patients on average were charged $3750.58 ± 1438.26 for their DMTs treatment dur-
ing the study period. However, the allowed amount by the health plan was $3547.05 
± 1380.56 and the actual paid amount was $3355.10 ± 1510.97. On average, patient’s 
deductible was $56.47 ± 401.03 and patient co-payment was $144.57 ± 371.65. For 
patients whose prescription was on their health plans formulary paid on average 
higher costs compared to patients who were not (paid amount $3406 vs $3223; 
allowed amount $3641 vs $3309). Even though most of the patients were females, 
but they had overall lower costs compared to males (amount allowed $3311 vs 
$3924; paid amount $3126 vs $3721; deductible $2.5 vs $155; co-payment $193 vs 
$66). Patients who received treatment in the east region of the USA had a higher 
costs compared to Midwest, south, and west regions (paid amount $3764 vs $3425 vs 
$3504 vs $3243). ConClusions: Costs were high for males and formulary status of 
the DMTs did not have an impact on the amount paid by the patients.
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objeCtives: The objective of this study is to assess the health care costs associ-
ated with Teriflunomide treatment for patients diagnosed with relapsing remitting 
multiple sclerosis (RRMS) in 2012 in the US Methods: A large US administrative 
retrospective claims database was used to identify patients diagnosed with RRMS 
and were prescribed Terfilunomide between September 2012 to December 2012 were 
included in the study. All patients were ≥ 18 years of age and continuously enrolled 
in the same health plan for a year. Descriptive statistics and chi-square tests were 
performed on the data. Results: There were a total of 157 patients that met the 
study inclusion criteria. Patients on average were charged $3816.90 ± 1702.83 for 
their treatment with Teriflunomide during the study period. However, the allowed 
amount by the health plan was $3635.28 ± 1314.56 and the actual paid amount was 
$3552.75 ± 1320.71. On average, patient’s deductible was $12.81 ± 96.33 and patient 
co-payment was $84.66 ± 184.95. For patients whose prescription was on their health 
plans formulary were charged less but paid more on the deductible and co-payment 
compared to patients who were not (charged amount $3646 vs $3829; deductible $14 
vs $11; co-payment $122 vs $63) on the formulary. Even though most of the patients 
were females, but they had overall lower costs compared to males (amount allowed 
$3475 vs $4057; paid amount $3391 vs $3980). Patients who received treatment in 
